Ipratropium Bromide And Albuterol Sulfate Solution
Product Images NDC 68788-8103

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ipratropium Bromide And Albuterol Sulfate (NDC 68788-8103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ipratropium Bromide 05mg And Albuterol Sulfate 3mg Inh Sol. (66f32a06 C880 4b5b 837b 951e1e01e040 00)

Ipratropium Bromide 05mg And Albuterol Sulfate 3mg Inh Sol. (66f32a06 C880 4b5b 837b 951e1e01e040 00)
This is a description of a medication called Ipratropium Bromide and Albuterol Sulfate inhalation solution, which comes in a 3mL unit-dose vial containing 0.5mg of ipratropium bromide and 3mg of albuterol sulfate. The medication is a generic version of Duoneb, used for oral inhalation. The packaging includes an expiration date and lot/batch numbers, and it is manufactured by Nephron SC Inc. The directions are not available in this text, and it includes a warning against transferring the drug to anyone other than the prescribed patient. It should be stored at temperatures between 2°C and 23°C, out of reach of children. The text includes several repetitions of the medication's name, lot/batch numbers, and production number, which could be related to inventory or distribution purposes.*
FDA Label Image

B5387e98-figure-01 (B5387e98 Figure 01)

FDA Label Image

B5387e98-figure-02 (B5387e98 Figure 02)

FDA Label Image

B5387e98-figure-03 (B5387e98 Figure 03)

B5387e98-figure-03 (B5387e98 Figure 03)
The text appears to be a mixture of numerical values, symbols, and a drug's name. The description of the drug is Albuterol and Ipratropium mixed together to create Mimutoral Sulfote Inhalation Solution. The rest of the text seems to be unreadable due to errors in .*
FDA Label Image

B5387e98-figure-04 (B5387e98 Figure 04)

B5387e98-figure-04 (B5387e98 Figure 04)
This is a report on adverse events caused by three different drugs used for respiratory conditions, namely Albuterol, Ipratropium, and Ipratropium Bromide. The report provides the number and percentage of patients who experienced adverse effects out of the total number of patients for each drug. Additionally, the report lists adverse events that occurred in more than 1% of patients in any one of the groups and where the combination treatment showed the highest percentage. The adverse events are grouped under different body systems, detailing the number and percentage of patients for each adverse event.*
FDA Label Image

B5387e98-figure-05 (B5387e98 Figure 05)

FDA Label Image

B5387e98-figure-06 (B5387e98 Figure 06)

FDA Label Image

B5387e98-figure-07 (B5387e98 Figure 07)

FDA Label Image

B5387e98-figure-08 (B5387e98 Figure 08)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.